Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials

Published:2021-12-01 Issue: Volume: Page:1-9
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Di Federico Alessandro¹²^ORCID,Rizzo Alessandro¹²,Carloni Riccardo¹²,De Giglio Andrea¹²,Bruno Riccardo²³,Ricci Dalia¹²,Brandi Giovanni¹²

Affiliation:

1. Division of Medical Oncology, Irccs Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy

2. Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Bologna, Italy

3. Department of Radiology, Irccs Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2009455

Reference85 articles.

1. The global cancer observatory cancer fact sheets. 2018. [cited 2021 Aug 14]. Available from: http://gco.iarc.fr/today

2. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

3. Novel advancements in the management of hepatocellular carcinoma in 2008

4. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

5. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Radioembolization Through Personalized Dosimetry;Advances in Clinical Radiology;2024-09

2. Amidoxime-based radio-microspheres for Internal Irradiation combined with a checkpoint-blocking nanobody boost antitumor immunity;Nano Today;2024-08

3. Selective internal radiation therapy for unresectable HCC: The SIRT downstaging study;Hepatology Communications;2024-06-27

4. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy;Cancers;2024-05-27

5. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?;Seminars in Liver Disease;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3